Your session is about to expire
← Back to Search
Antibody
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease
Phase 1
Waitlist Available
Led By Beth E. Safirstein, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 weeks
Summary
This trial tests MEDI1341, a drug given through an injection, in people with Parkinson's Disease. The goal is to see if it can help improve movement and reduce symptoms. Participants will receive the treatment multiple times over a few months, and the study will last several months per person.
Eligible Conditions
- Parkinson's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Body Weight
Impaired cognition
+7 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MEDI1341Experimental Treatment1 Intervention
3 doses given at 4 week intervals
Group II: PlaceboPlacebo Group1 Intervention
3 doses given at 4 week intervals
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI1341
2020
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,411 Previous Clinical Trials
289,123,568 Total Patients Enrolled
TakedaIndustry Sponsor
1,238 Previous Clinical Trials
4,148,993 Total Patients Enrolled
Beth E. Safirstein, MDPrincipal InvestigatorMD Clinical
1 Previous Clinical Trials
67 Total Patients Enrolled